As an experienced pharma consulting firm, we are proud to support companies developing innovative and life-changing medicines.

We enjoy collaborating with Invitris, a spin-off from the Technical University of Munich, that is developing a groundbreaking platform for scaling the synthesis of antimicrobial proteins like bacteriophages. These medications are intended as an alternative to antibiotics in the fight against multi-resistant bacteria.

To ensure the necessary GMP standards in production, Invitris has teamed up with PharmaKorell to conduct exploratory audits of potential production sites.

We wish Dr. Patrick Grossmann, Dr. Kilian Vogele, and their team all the best for the next phase of their scaling activities, made possible thanks to the recently approved stage-2 funding from INCATEurope, the European incubator for antibacterial therapies.